Understanding multiple myeloma pathogenesis in the bone marrow to identify new therapeutic targets

Teru Hideshima, Constantine Mitsiades, Giovanni Tonon, Paul G. Richardson, Kenneth C. Anderson

Research output: Contribution to journalArticlepeer-review

Abstract

Multiple myeloma is a plasma cell malignancy characterized by complex heterogeneous cytogenetic abnormalities. The bone marrow microenvironment promotes multiple myeloma cell growth and resistance to conventional therapies. Although multiple myeloma remains incurable, novel targeted agents, used alone or in combination, have shown great promise to overcome conventional drug resistance and improve patient outcome. Recent oncogenomic studies have further advanced our understanding of the molecular pathogenesis of multiple myeloma, providing the framework for new prognostic classification and identifying new therapeutic targets.

Original languageEnglish
Pages (from-to)585-598
Number of pages14
JournalNature Reviews Cancer
Volume7
Issue number8
DOIs
Publication statusPublished - Aug 19 2007

ASJC Scopus subject areas

  • Cancer Research

Fingerprint

Dive into the research topics of 'Understanding multiple myeloma pathogenesis in the bone marrow to identify new therapeutic targets'. Together they form a unique fingerprint.

Cite this